Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 11/20 | 0.56 |
| ▸ | GRK3 | P35626 | 8/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | GRK5 | P34947 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535879 | 0.88 | GRK2 (0.57) | GRK2GRK3ROCK2GRK5LMNA | |
| SCHEMBL5329635 | 0.87 | GRK2 (0.55) | GRK2GRK3ROCK2GRK5 | |
| SCHEMBL5545993 | 0.85 | GRK2 (0.59) | GRK2GRK3ROCK2LMNAMAPT | |
| SCHEMBL5536140 | 0.82 | CYP17A1 (0.47) | GRK2GRK3ROCK2GRK5MAPT | |
| SCHEMBL5533102 | 0.82 | GRK2 (0.58) | GRK2GRK3ROCK2GRK5KDR | |
| SCHEMBL5533006 | 0.79 | GRK2 (0.64) | GRK2POLBSMN1; SMN2 | |
| SCHEMBL5533048 | 0.78 | CA1 (0.57) | GRK2GRK3ROCK2GRK5MAPT | |
| SCHEMBL5537408 | 0.78 | GRK2 (0.43) | GRK2GRK3ROCK2GRK5LMNA | |
| SCHEMBL5543418 | 0.77 | GRK2 (0.56) | GRK2GRK3ROCK2GRK5LMNA | |
| SCHEMBL5537464 | 0.75 | CYP17A1 (0.39) | GRK2GRK3ROCK2GRK5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | GRK4, GRK2, GRK1 | GRK2 2/4885GRK3 4/4885ROCK2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.